| Name | Title | Contact Details |
|---|
Brightseed enables a healthier future by illuminating and activating the connections between people and plants. Despite centuries of wisdom proving the critical roles plants play in supporting our health, the majority of active compounds in the plant kingdom remain unexplored. Our artificial intelligence, Forager®, reveals powerful compounds hidden in nature and our team scientifically validates their impact.
Botanix Pharmaceuticals is a biotechnology company listed on the ASX (ASX: BOT) with headquarters in Perth, Australia, and Philadelphia, USA. The company specializes in clinical-stage dermatology and antimicrobial treatments, focusing on synthetic cannabinoid-based therapies that utilize cannabidiol (CBD) and its proprietary skin-delivery technology, Permetrex™. The companys product pipeline includes several innovative therapies aimed at addressing common dermatological conditions. These include BTX 1503 for moderate-to-severe acne, BTX 1702 for rosacea, and BTX 1204A for moderate atopic dermatitis. Additionally, BTX 1801 targets infections in hemodialysis patients and other antimicrobial applications. All products leverage the Permetrex™ delivery system to enhance skin absorption, and Botanix is also exploring veterinary applications for atopic dermatitis. Botanix aims to improve patient outcomes by addressing unmet needs in dermatology and antimicrobial resistance, positioning itself as a leader in cannabinoid-based dermatological treatments.
Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded by Darell Bigner, MD, and Matthias Gromeier, MD, of Duke University Medical Center in 2016. Both are leaders in their respective research fields of virology, immunology, monoclonal development and clinical medicine, particularly in the treatment of brain tumors.
VEXIOM HOLDINGS CORPORATION is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arranta Bio is delivering on its vision to build the best-in-class microbiome contract development and manufacturing organization (CDMO) through our merger with a 10-year veteran CDMO, Captozyme, and the establishment of a commercial-ready manufacturing facility. We provide manufacturing and development support for live biotherapeutic products (LBPs) targeting gut health and microbiome-related diseases by providing development and manufacturing services that bring effective treatments to the market and patients in need.